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1 |  INTRODUCTION
The treatment of melanoma has changed significantly over 
the last decade. Three classes of new treatment approaches—
BRAF inhibitors, immune checkpoint therapy (CTLA‐4 and 
PD‐1 antibodies), and oncolytic viruses, have been devel-
oped, and several new agents have been approved.1
Nivolumab is one of the monoclonal anti‐PD‐1 antibody 
treatments. Nivolumab binds to the PD‐1 ligand, which is 
expressed on tumor cells. Normally, the PD‐1 receptor is ex-
pressed on B and T cells, as well as on monocytes and natu-
ral killer cells. Tumor cells express the PD‐1 receptor ligand 
that inhibits the proliferation and survival of CD8+ cytotoxic 
cells.2 Nivolumab and another anti‐PD‐1 agent, pembroli-
zumab, have recently been registered by FDA as treatment 
for metastatic melanoma. The results of clinical trials showed 
increased response rates and overall survival in comparison 
with standard chemotherapy.3,4
Although significant progress has been made, current 
immune checkpoint therapies cause severe adverse events 
and better overall survival is still needed.5 To improve over-
all survival in patients, several new clinical trials focus on 
combination therapies. Mainly, immune checkpoint therapies 
are combined with other therapies such as oncolytic viruses.1
Rigvir is an oncolytic ECHO‐7 virus strain belonging to 
the Picornaviridae family, Enterovirus genus. Rigvir is a pos-
itive sense single‐stranded RNA virus selected and adapted 
for melanoma.6 In a postmarketing retrospective study, stage 
IB and stage II melanoma patients that had received Rigvir 
therapy had 4.39‐ to 6.57‐fold lower mortality than the ob-
servation group.7
Here, we report a case where a metastatic melanoma pa-
tient has been treated with the oncolytic virus Rigvir and the 
PD‐1 monoclonal antibody nivolumab.
2 |  CASE DESCRIPTION
A male patient at the age of 35 noticed a mole on his right 
shoulder and underwent surgical removal of the mole. 
Histological examination suggested stage IIC nodular mela-
noma (pT4bN0M0), invasion level by Clark III, Breslow's 
depth 4.5 mm with ulceration, and excision with tumor dis-
tance of 2.2 mm from lateral surgical margin ((Figure 1A), 
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Abstract
A 35‐year‐old male patient was diagnosed with stage IIC skin melanoma that rapidly 
progressed after surgery. Treatment was continued with radiotherapy, which did not 
stop further spread of disease and the patient was put on a combination of nivolumab 
and Rigvir. Subsequently, the progression has slowed.
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HMB‐45 positive (Figure 1B)). Up to three mitoses per 
1 mm2 were observed in dermal component of the tumor. The 
pathological examination of the sentinel node was negative. 
However, after a month the patient felt a growth in the area 
of right shoulder blade. After a month, a scar widening and 
removal of three sentinel lymph nodes were performed. All 
nodes were without malignant changes. At 2.2 months, me-
tastases in the right collar bone and under the right shoulder 
(classified as nodular and local recurrence) were detected. 
The tumor was negative for BRAF V600E mutation. At 
3.2 months, new metastases above the right collar bone and 
under the right shoulder appeared, and eight lymph nodes 
F I G U R E  1  (A) Histological microphotographs. Skin invasive ulcerated nodular melanoma, invasion III level by Clark. Hematoxylin and 
eosin stain (x25; inclusion HE x 400). Scale bar is 2 mm. (B) Skin invasive nodular melanoma. Positive HMB‐45 antibody stain (x150). Scale bar 
is 300 μm. (C) Melanoma metastasis (19 mm) in lymph node, at 3.7 mo. Hematoxylin and eosin stain (x20; inclusion HE x 400). Scale bar is 3 mm. 
(D) Skin invasive nodular melanoma. Ki67 antibody stain (x20). Scale bar is 200 μm
(A) (B) (C) (D)
F I G U R E  2  Contrast‐enhanced CT scans at (A) 6.6 mo show several lung nodules, with largest nodule in the lingular lobe of the left lung. 
Lung nodules and enlarged lymph nodes in mediastinum are not seen at (B) 10.2 mo, (C) at 1.3 y, and (D) at 1.5 y showed no change in size
(A) (B) (C) (D)
F I G U R E  3  (A, B, C) Contrast‐enhanced CT scans reveal enlarged lymph nodes in the mediastinum with the largest diameter of 1.4 cm at 
6.6 mo. CT scans show no enlarged lymph nodes in the mediastinum at (D, E, F) 10.2 mo, (G, H, I) 1.3 y, and (J, K, L) 1.5 y
(A)
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above the right collar bone were removed; the histopathology 
report confirmed melanoma metastasis (of 19 mm diameter) 
in one lymph node (Figure 1C). Immunohistochemically, pri-
mary tumor and metastases excised at 2.2  months showed 
moderate/strong cytoplasmic staining in 50% of atypical cells 
for HMB‐45, moderate/strong cytoplasmic staining in 95% 
of atypical cells for MelanA, and strong cytoplasmic and nu-
clear staining in 100% of atypical cells for S100. Ki67 prolif-
eration index was not more than 20% (Figure 1D).
Between 4.7 and 5.3 months, the patient received radio-
therapy to the right axilla, right shoulder blade, and right cla-
vicula (9 × 4 Gy, 36 Gy in total).
At 5 months, excision of one node from the right armpit 
was performed and the whole node was full of melanoma me-
tastasis. A CT chest scan at 6.6 months detected a neoplastic 
process spreading to the right lobe of the lung and medias-
tinum on both sides, and two large lumps in the right lung 
suggested metastases (Figure 2A, 3A‐C). Pathological lymph 
nodes in the left side of mesentery were detected at 7 months 
(Figure 4A). Hypovascular focal lesions in the right liver lobe 
and spleen, enlarged lymph node in hepatic hilus, were also 
observed (Figure 5A,B).
At 7.2 months, according to CT scans (Figures 4A and 
5A,B) disease progression to the liver, spleen, and abdomi-
nal lymph nodes was once again suspected. At 7.3 months, 
the patient started immunotherapy with nivolumab 3  mg/
kg (240  mg) iv infusions (2‐week intervals), and at 
7.8  months—patient started virotherapy with Rigvir 2  ml 
(im also 2‐week intervals on alternating weeks). The patient 
has received 32 injections of Rigvir and 32 injections of 
nivolumab during 1.3‐year period. Both therapies are still 
ongoing. The progression of disease and therapy dates is 
represented in Figure 6.
At 9.8 months, no lung nodules or enlarged lymph nodes 
in mediastinum were detected (Figure 2B). Lymph node in 
left mesentery had decreased in size to 1  cm (Figure 4B). 
Lesion in right liver lobe had disappeared and lymph node in 
hepatic hilus decreased in size (Figure 5C,D).
After 1.2 years, the disease progressed to lymph nodes 
in the mesogastrium (Figure 4C); however, the lung me-
tastases were stable (Figure 2C). The patient underwent 
laparoscopic resection of a mesogastric lymph node at 
1.5 years; the histopathological report after surgery ver-
ified melanoma metastases in one of six lymph nodes 
in the mesentery of the small intestine. Tumor cells ex-
hibited severe nuclear atypia, 8 mitosis in 10 HPF (ap-
prox. 1.5 mitoses per 1 mm2) and necrosis of about 50% 
of tumor area. No extranodal spread was visible. PD‐L1 
immunohistochemical reaction (with antibodies of Dako 
clone 22C3) was performed on a posttherapy metastasis 
and a primary skin melanoma sample; the reaction was 
negative in both samples (weak incomplete membranous 
reaction was observed in less than 1% of the melanoma 
cells).
At 1.5 years, the CT scan suggests that the lesion in left 
mesentery has been reduced in size (Figure 4D). No lesions 
were observed in liver, hepatic hilus, or spleen (Figure 5E,F). 
Overall, the radiological findings are stable in comparison 
with findings at 1.3 years (Figure 3J,K,L, 4D, 5G).
No other health problems have been reported. Current 
ECOG performance status is 0.
Throughout the treatment with Rigvir, the patient has not 
reported any side effects; also, tolerance of nivolumab has 
been satisfactory. The patient noted some neuropathic pain 
after nivolumab infusions. After the patient received the first 
nivolumab injection (before start of Rigvir treatment), there 
was a slight elevation of blood glucose that remains slightly 
elevated.
It has previously been reported that nivolumab may 
cause impaired glucose tolerance or autoimmune diabe-
tes.8-11 The available blood sample tests from 6.6 months 
to 1.3 years show that all values, except for glucose values 
(Grade 1 according to NCI CTCAE), were in the normal 
range. At 7.6 months, the overnight fasting blood glucose 
was reported to be 6.1  mmol/L, at 1.1‐year 6.2  mmol/L 
and at 1.3‐year 6.1  mmol/L. A slight elevation of blood 
glucose levels has been observed both in melanoma pa-
tients that are only observed and that have been treated 
with Rigvir.7
The patient was a long‐term smoker (20 cigarettes per day) 
for about 18  years; smoking was discontinued 2‐3  months 
after diagnosis. The patient has worked as a civil engineer for 
F I G U R E  4  Contrast‐enhanced CT scans reveal pathological lymph nodes in the left side of the mesentery with the largest lymph node of 
up to 2 cm in the largest diameter at (A) 7 mo that has decreased in size to 1 cm in the largest diameter at (B) 10.2 mo. (C) Decrease in size was 
observed from 1.3 y when the lymph node had increased to 1.6 cm. At (D) 1.5 y, the size of the lymph node has decreased to 0.9 cm
(A) (B) (C) (D)
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many years and has had high sun exposure, working outdoors 
without the protection from sun.
3 |  DISCUSSION
Dendritic cells take up fragments of dying cancer cells and 
display them as tumor‐associated antigens.12 Dendritic cells 
migrate to tumor‐draining lymph nodes where T cells are 
primed. Activated T cells migrate back to the tumor, recog-
nize, and lyse tumor cells. However, tumors have mecha-
nisms that help them to escape the immune system. Tumor 
cells may prevent dendritic cell maturation; then T cells are 
not activated, and immune tolerance is induced. Inhibited 
dendritic cell maturation also has a negative effect on pro-
duction of chemokines, which normally recruit T cells to the 
tumor. Tumors also affect the vascular endothelium. Factors 
like vascular endothelial growth factor suppress production 
of adhesion molecules required for T‐cell adhesion to en-
dothelium and induce expression of immune inhibitory and 
cytotoxic molecules.12
Only a limited number of patients respond to PD‐1 block-
ade therapy. The explanation appears to be that if no CD8+ 
T cells are present in the tumor, the patient will not respond 
to the therapy. Therefore, it is important to attract CD8+ cells 
into the tumor microenvironment, which would improve 
the effect of PD‐1 antibodies.1 Oncolytic viruses have been 
demonstrated to besides tumor lysis, also activate antitumor 
immune response.13
Several recent clinical trials have investigated the possible 
synergistic effect of immune checkpoint inhibitors with onco-
lytic viruses. For example, in a phase Ib study, Coxsackie A21 
F I G U R E  5  Abdominal contrast‐enhanced CT late phase scans at 6.6 mo show (A) a hypovascular focal lesion in the right lobe of the liver 
of up to 1 cm in diameter and (B) in the spleen up to 1 cm. (C, D) In the scan at 10.2 mo, the lesion in right liver lobe of the liver had disappeared 
and the lymph node in the hepatic hilus has been reduced in size. (E, F) At 1.3 y and (G) at 1.5 y, there is no change in size of the lymph nodes and 
lesions in the liver are not observed
(A)
(B)
(C)
(D)
(E)
(F) (G)
F I G U R E  6  Therapy plan and disease 
progression dates
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virus was administered in combination with pembrolizumab 
and showed preliminary best overall response (complete and 
partial response according to immune‐related response crite-
ria) rate in 61.0% (14/23 patients). Combination of Coxsackie 
A21 and pembrolizumab showed clinical benefit, and the 
possible synergistic mechanism was explained by increased 
immune cell infiltration into tumor lesions, activation of 
RIG‐I pathway, upregulation of gamma‐INF response and 
key immune checkpoint genes, including PD‐L1, caused by 
intratumoral Coxsackie A21 virus injections. Upregulation 
of PD‐1L expression on tumor cells increases the effect of 
pembrolizumab.14
Combination of talimogene laherparepvec and ipilimumab 
has been evaluated in a phase Ib and phase II studies, both 
showing higher efficacy in combination than as a monother-
apy of talimogene laherparepvec or ipilimumab alone.15,16
Talimogene laherparepvec intralesional injections before 
pembrolizumab administration promoted the CD8+ cell in-
filtration into tumor. Systemic increase in CD4+ and CD8+ 
cells was also observed. CD8+ T cells express PD‐1 receptor 
that binds to tumor PD‐1L; therefore, increased CD8+ cell 
count could benefit to combination therapy with anti‐PD‐1 
antibodies.
A case series evaluated talimogene laherparepvec in com-
bination with PD‐1‐based immunotherapy in unresectable 
stage III and IV melanoma patients. Ten patients with unre-
sectable stage IIIC to IVM1b melanoma were treated with tal-
imogene laherparepvec and checkpoint inhibitor. All patients 
had different treatment plans as well as previous treatment 
history. The study was too short to provide median survival 
or 12‐month survival rates; however, complete response was 
observed in 60% of the patients.
The data suggest that radiation therapy prior to immune 
therapy may enhance the effect of the immune therapy. 
Radiation therapy induces the release of tumor‐associated 
antigens that, in turn, play essential role in priming adaptive 
immune system17,18; some encouraging reports have been 
published.19,20 However, the present patient experienced dis-
ease progression after the radiation therapy.
Overall, the present result suggests that combination of an 
oncolytic virus and an immune checkpoint inhibitor could be 
of benefit for patients without causing additional toxicities. 
The present clinical case shows a patient that had a rapidly 
progressing metastatic melanoma. The combination of onco-
lytic virotherapy with Rigvir and a PD‐1 antibody has slowed 
the progression. The combination is well tolerated since no 
new toxicities have been reported.
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